Drk-Blutspendedienst Rheinland-Pfalz UND Saarland Gemeinnützige Gesellschaft MIT Beschränkter Haftung

Drk-Blutspendedienst Rheinland-Pfalz UND Saarland Gemeinnuetzige Gesellschaft MIT Beschraenkter Haftung, doing business as "Drk-Blutspendedienst Rheinland-Pfalz, Saarland," supplies blood and blood products to the Defense Health Agency as a prime contractor under full-and-open competition, with all recent work performed in Germany to support U.S. military healthcare facilities in the European theater, including Landstuhl Regional Medical Center.

The vendor is a for-profit organization headquartered in Bad Kreuznach, Germany, with an operational footprint centered on blood bank supplies and blood products (NAICS Blood and Organ Banks; primary PSC Drugs and Biologicals). The vendor holds a single-award Blanket Purchase Agreement with the Defense Health Agency, awarded January 25, 2023, with a $500,000 ceiling and performance extending through January 17, 2028. All work is firm fixed-price and open competition; no set-aside designations apply across the award history.

Customer concentration is absolute: the Defense Health Agency accounts for 100% of the vendor's tracked federal award footprint, representing eight awards and $867,000 in combined potential value over the past three-plus years. The vendor operates entirely under the single-award BPA W9114F23A0003, which has generated seven task orders ranging between approximately $26,000 and $93,700 in individual ceiling value. Recent calls include a $93,708.51 BPA call issued March 5, 2026, for emergent FY26 blood supply requirements at Landstuhl Regional Medical Center through September 30, 2026; a $74,476.12 call issued January 1, 2026, through September 30, 2026; a $31,779.07 call issued October 1, 2025, through December 31, 2025; and a $52,660.83 call issued January 1, 2025, through September 30, 2025. Activity has remained steady at two awards per year across 2023 through 2026. Within the next twenty-four months, two awards (combined potential value $168,000) face ultimate completion and thus represent recompete risk for the vendor. To date, $366,000 of the $867,000 combined potential value has been obligated (42% draw-down rate).